Related Experiment Video
Updated: Mar 6, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Navigating the evolving therapeutic landscape in advanced prostate cancer
E David Crawford1, Daniel Petrylak2, Oliver Sartor3
1Department of Surgery, Section of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO.
Urologic Oncology
|March 12, 2017
Summary
Prostate cancer can progress to castration-resistant prostate cancer (CRPC) despite treatment. Biomarkers are crucial for guiding therapy selection and improving outcomes in advanced prostate cancer patients.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is a leading cause of cancer in men.
- Up to 20% of patients develop castration-resistant prostate cancer (CRPC) within 5 years of treatment.
- Metastatic CRPC has a median survival of 15-36 months.
Purpose of the Study:
- To discuss the challenges in sequencing and combining therapies for CRPC.
- To explore the role of biomarkers in optimizing treatment selection for advanced prostate cancer.
- To review ongoing research in prognostic and predictive biomarkers for CRPC.
Main Methods:
- Literature review of current prostate cancer treatment strategies.
- Discussion of the androgen receptor's role in therapy and resistance.
- Analysis of the development and application of biomarkers in CRPC management.
Main Results:
- Several new drugs for CRPC have emerged in recent years.
- Understanding disease mechanisms aids in biomarker development.
- Biomarkers can help personalize treatment by predicting patient response and tolerance.
Conclusions:
- Optimizing CRPC treatment requires careful consideration of therapy sequencing and combinations.
- Biomarker research is essential for guiding the selection of appropriate agents for individual patients.
- Continued research into prognostic and predictive biomarkers will improve outcomes for advanced prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K